XCath to Perform Live Telerobotic Trial Procedure at Abu Dhabi Global Healthcare Week

Live showcase of remote robotic capability for emergent interventional procedures

HOUSTON–(BUSINESS WIRE)–XCath, an early-stage medical device company dedicated to expanding endovascular treatment modalities through its smart steerable guidewires and robotic systems, will exhibit its technology through innovation sessions at Abu Dhabi Global Healthcare Week (ADGHW) hosted by the Abu Dhabi Department of Health (DoH). The demonstration will include a live telerobotic trial procedure between Abu Dhabi and South Korea on May 15^th at 11:00 am GST, demonstrating the XCath platform’s potential to support remote minimally invasive procedures for the management of acute neurovascular conditions. Dr. Vitor Mendes Pereira, Director of Endovascular Research and Innovation at St. Michael’s Hospital in Toronto, Canada, will perform the live trial demonstration.

ADGHW will take place May 13-15 in Abu Dhabi, uniting global healthcare leaders, policymakers and stakeholders to examine worldwide trends and industry challenges.

“By enabling telerobotic procedures, we can provide a solution for reimagining complex care,” said Eduardo Fonseca, CEO of XCath. “Dr. Pereira is a pioneer in endovascular neurosurgery and shares our vision for advancing telerobotic treatment options, which has become a humanitarian and economic imperative for conditions such as stroke. His telerobotic demonstration will show the viability of our platform as a solution to meet the global demand for new treatment options to expand access to care for patients globally.”

In the session XCath will introduce the company, navigation challenges, and an overview of its platform. XCath will also spotlight the transformative impact of the endovascular revolution in healthcare, illustrating how expert navigation through our body’s extensive highway of blood vessels has transformed clinical outcomes.

“ADGHW is a tremendous opportunity for XCath to display its concept on an international stage,” said Neeraj Agrawal, Executive Director of Crescent Enterprises and XCath Board Member. “Crescent Enterprises is dedicated to helping disruptive companies foster growth and innovation in the Middle East, and XCath’s presentation will increase awareness surrounding venture capital investments in the area.”

Dr. Pereira performed the world’s first robotic-assisted neurointerventional procedure in 2019, a stent-assisted coiling procedure to treat a large basilar aneurysm. He serves as a Professor of Surgery and Medical Imaging at the University of Toronto and is the lead scientist of the RADIS lab, which focuses on applying innovative technologies on the treatment of neurovascular diseases.

For more information about ADGHW, visit https://www.adghw.com/. To learn more about XCath, visit https://www.xcath.com/.

About XCath

Founded in 2017, XCath is a dynamic startup at the cutting edge of revolutionary medical robotics, nanorobtics and materials science. XCath develops next-generation endovascular robotic systems and steerable guidewires to treat life-threatening conditions like cerebrovascular disorders. With strategically located campuses in Houston, Texas – home to the world’s largest medical center – and Pangyo, South Korea, often referred to as the Silicon Valley of Korea, XCath is committed to bringing its innovative solutions to patients around the world.

The XCath steerable guidewires and endovascular robotic systems are currently under development. They are not yet cleared for commercial distribution in any country.

Contacts

Dan Ventresca

Matter Health for XCath

XCath@matternow.com